Bristol's Abatacept, Muraglitazar To Go Before Advisory Committees In September

Orencia (abatacept) for moderately to severely active rheumatoid arthritis will be reviewed by FDA's Arthritis Drugs Advisory Commmittee. Pargluva (muraglitazar) will be considered by FDA's Endocrinologic & Metabolic Drugs Advisory Committee for type II diabetes mellitus.